Comparative Study of Prophylactic Rectal Indomethacin and/or Papillary Spray of Adrenaline in Prevention of Post-ERCP Pancreatitis in Patients with Sphincterotomy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202501795806576

Enrollment

200

Registered

2025-01-15

Start date

2025-01-04

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

control group

Indomethacin group

Epinephrin spray group

Combined group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any patient with age above 18 years old and scheduled for ERCP for any cause was eligible for the study

Exclusion criteria

Exclusion criteria: Contraindications to ERCP Allergy to epinephrine or NSAIDs Patients received NSAIDs within 7 days before the procedure Gastrointestinal hemorrhage within 4 weeks Renal dysfunction [creatinine> 1.4mg/dl or 120 umol/1] Presence of coagulopathy before the procedure Acute pancreatitis within 3 days before the procedure Pregnant or breastfeeding women

Design outcomes

Primary

Measure	Time frame
serum amylase or lipase = 3 times the upper limit of normal value	—

Secondary

Measure	Time frame
the severity of post-ERCP pancreatitis	—

Countries

Egypt

Contacts

Public ContactHamdy Moustafa

professor of hepatology gastroenterology and infectious diseases

dr.hamdymm511@gmail.com01006698741

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026